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The Strange Story of Jay McLean, the Discoverer of Heparin 
C o n r a d R. L a m , M D * 
Since 1939, the use of heparin has become widespread 
in the prevention of postoperative thrombosis and em-
bolism and is the basis for modern open-heart surgery. 
What is not generally known is the story of Jay McLean, 
the second-year medical student at Johns Hopkins who 
is given credit for the original discovery. McLean's first 
scientific publication concerning the use of heparin 
M o s t articles that deal wi th the history of heparin 
begin with the statement, "Heparin was discovered by 
Jay McLean in Howell 's laboratory at Johns Hopkins in 
1916." This assertion is based on McLean's 1916 paper 
"The Thromboplastic Action of Cephal in" (1) in which 
he describes his original experiment wi th the sub-
stance. However, the word "hepar in " is neither in the 
tit le nor in the body of the paper. It was 25 years before 
McLean's name appeared as the coauthor of a brief 
clinical paper report ing the failure of heparin and sul-
fapyridine to cure two cases of subacute bacterial endo-
carditis (2). What was McLean doing dur ing those 25 
years after his important discovery? 
My early interest in heparin and a personal acquain-
tanceship wi th McLean in the 1940s has prompted me to 
probe into his life story. The story, as it has unfolded, 
paints the pathetic picture of an insecure individual who 
had many disappointments in life. His biography has 
been diff icult to piece together, but the version 1 have 
assembled, although fragmentary, is the most complete 
I have seen. The most cohesive account available is an 
article by A. McGehee Harvey, "Fountainhead of Am-
erican Physiology: H. Newell Martin and His Pupil, 
Wil l iam Henry Howe l l " (3). Since Howell 's main interest 
after 1909 was in the coagulation of b lood, an account of 
his work in this f ield would necessarily include some-
thing about McLean. 
McLean was born in San Francisco in 1890, had a year of 
medical schooling there, came to Baltimore in 1914, and 
was admitted to Johns Hopkins Medicai Schooi in 1915, 
from which he received the M D degree in 1919. 
McLean was a second-year medical student at Johns 
Hopkins when Howell assigned him the problem of 
identifying the active principle in a number of sub-
stances known or suspected of being thromboplastic. 
In McLean's words, "A t the suggestion of Dr Howell I 
have undertaken a re-examination of this subject to 
determine if possible whether the thromboplastic effect 
may be attributed to an impuri ty, or is a property of 
does nof contain the word "heparin," and not until 25 
years later did McLean publish a short paper about 
heparin. Some personal letters and other research have 
indicated a checkered career. He was trained as a sur-
geon in the Halsted school but was practicing ther-
apeutic radiology when he died in Savannah in 1957. 
cephalin itself, and also to determine in how far a similar 
property is exhibited by other related phosphatids , . . 
cephalin, leci thin, sphingomyel in, cuor in, and hep-
arphosphatid" (1). And on pages 255-6: (words in par-
entheses are mine) "The cuorin (from heart) on the 
contrary when puri f ied by repeated precipitation in 
alcohol at 60°, has no thromboplastic effect—indeed it 
possesses an anticoagulating power as may be illus-
trated by the fo l low ing exper iment . . . . The hep-
arphosphatid on the other hand when purif ied by many 
precipitations in alcohol at 60° has no thromboplastic 
action and in fact shows a marked power to inhibit 
coagulation. The anticoagulating action of this phos-
phatid is being studied and wi l l be reported upon later." 
The subsequent studies and report were not made by 
McLean, who presumably f inished his rotation to How-
ell's laboratory and went ahead wi th his medical school 
studies. But Howell lost no t ime in pursuing the promis-
ing lead opened up by McLean and, wi th the help of 
Emmett Holt (a retired, eminent pediatrician), made an 
extensive study of the heparphosphatid. In their paper 
published in 1918 (4), the anticoagulant was named 
"hepar in " because it came from a dog's liver. In a later 
paper, Howell (5) described further purification of hep-
arin, which resulted in a marked increase in potency. 
But the agent was still not ready for clinical use until the 
late 1930s when a highly purif ied product was made 
independently in Toronto (6), Denmark (7), and Sweden 
(8). 
During this t ime where was the discoverer of heparin, 
Jay McLean? Harvey's account states that after his 
graduation in 1919, he was a member of the surgical 
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house staff (intern?) at Johns Hopkins Hospital and was 
an instructor in surgery f rom 1921-1924. In 1920, he had 
his rotation to the Hunterian Laboratory (surgical ex-
perimental laboratory) and while there, he received a 
warm letter f rom Harvey Cushing, the famed neuro-
surgeon of Boston who had established the laboratory 
in 1905. The letter gave the history of the laboratory and 
as printed in John Fulton's biography of Cushing, it 
occupied five printed pages (9). A picture o f the resident 
surgical staff at Hopkins about 1921 shows McLean in 
rather fast company, judging f rom the later careers of 
many of his colleagues. Among these were Emile Hol-
man, later Professor of Surgery at Stanford; Wil l iam 
Reinhoff, later a prominent thoracic surgeon; Warf ield 
Firor, who for a time was Chief of Surgery at Hopkins; 
Deryl Hart, the first head of the Department of Surgery 
at Duke University; and Max Zinninger, a prominent 
surgeon of Cincinnati (Fig 1). Harvey presented a curi-
ous quotat ion f rom McLean: "Concern ing the dis-
covery of heparin, he stated: 'The discovery of heparin 
came as a result of my determination to accomplish 
something by my own ability. It was this determination 
to become a physiologically-based surgeon, rather than 
an anatomy-based surgeon that led to the discovery of 
heparin. '" If that was really his ambit ion, he could have 
made a better choice of a service for postgraduate 
experience. The Halsted School of Surgery, and espe-
ry Ford Hospital 
Hospital, 2799 V 
are in the Henfy 
.1 
cially the Hunterian Laboratory, trained surgeons who 
were expected to be expert wi th the scalpel (10). One 
wonders if he did not make that statement after it was 
evident that he would not make his mark in the oper-
ating room. It is curious that in my extensive file on h im, 
there is no evidence that he ever performed an oper-
ation, although he must have been on the surgical staff 
at Hopkins for five years. 
After 1924, McLean became instructor in surgery at the 
University of California, and f rom 1943 to 1947 he was 
Associate Professor of Experimental Surgery at Oh io 
State University. Obviously, there is a gap of 19 years 
between the t ime he went to California and the t ime he 
came to Columbus. 
By 1945, I had become acquainted with Jay through 
considerable correspondence and dur ing his two visits 
to Detroit. In a letter dated June 29,1945, he stated that 
he had worked with James Ewing, the pathologist, for 
the 12 years between 1927 and 1939. A biography of 
Ewing indicates that he was Professor of Pathology at 
Cornell 1899-1932, and Professor of Oncology until his 
death in 1943. In the latter capacity, he might have had 
some clinical practice, but it is hard to see why a man 
with five years of surgical training would spend that 
much t ime with a pathologist, even a great one like 
Ewing. 
f 
Figi 
Resident surgical staff at the lohns Hopkins Hospital c 1921. Front row: 
left, Rienhoff; center, Holman; extreme right, McLean. Back row: center, 
Firor; next to right, Hart; extreme right, Zinninger. Courtesy of |ohns 
Hopkins University Press (10). 
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A possible clue to McLean's whereabouts before he 
worked with Ewing may be found in an obituary that 
appeared in a Buenos Aires medical news publication 
in 1957 (11): (translation) " A native of Cal i fornia, 
Dr McLean was graduated from the famous Johns Hop-
kins Hospital of Baltimore. He studied in France at the 
Salpetriere and in the Hospital of St Jacob in Leipzig, 
Germany . . . " I have no further documentation of this 
foreign study, but the fact that the rest of the article 
agrees w i t h known facts lends c red ib i l i t y to the 
statement. 
Some time between 1939 and 1941, McLean moved to 
Columbus. A letter f rom him to me, dated Oct 31,1941 
has turned up in my file on heparin. The stationery has 
the letterhead "Drs Edward Reinert and Jay McLean, 245 
East State Street, Columbus, O h i o . " It was typed and 
signed by a secretary over McLean's name. "Dear 
Dr Lam: I am preparing a monograph on Heparin, I 
would be greatly pleased i fyou would send me a reprint 
of your article: 'Heparin administration: methods and 
results in thirty cases,' appearing in Annals of Surgery, 
Aug, 1941 (114:205)." There is a notation on the letter by 
my secretary "mai led reprint, 11-11-41." I received a 
cordial reply on a penny postcard dated Nov 18: " I 
thank you for the reprint of your article. . . . I heard 
much favorable about your exhibit at the last AMA 
Convention and I am sorry I could not see it. Sincerely, 
Jay McLean." 
If he had come by my exhibit on "Heparin Admin-
istration" at the annual meeting of the American Medi-
cal Associat ion in C leve land , he might have en-
countered two other visitors whose names are indelibly 
associated with the history of heparin, his former chief 
Professor Howell and Charles H. Best, codiscoverer of 
insulin. Dr Best had encouraged the final purif ication of 
heparin by Charles and Scott (6) and collaborated with 
the Canadian surgeon Gordon Murray in early clinical 
trials (12). However, these two scientists might have 
been iess than cordial to the discoverer of heparin. 
McLean seemed to have developed an antipathy toward 
Howell . On Oct 25, 1943, he wrote Dr McClure* : " In 
going over some old correspondence today, I came 
across a letter to me from Dr Howel l , dated from Wash-
ington DC (when he was on the National Research 
Council), October 27,1931. Apar t of one paragraph isaa 
fol lows: 'Doctor McClure of the Ford Hospital, Detroit 
wanted to use heparin as a routine procedure after a l l 
operations as a preventive of post-operative t h r o m i 
bosis, but it seemed to me that this was a risky idea, 
since if it were used immediately after the operation ifj 
might cause troublesome hemorrhage.' That was i n 
1931! What a shame the idea could not have beeri 
developed by you instead of the Toronto and Stockl 
holm Schools. As you know, I am wri t ing a monograph 
on heparin, which includes the history of heparin; and 
if you should care to entrust to me the letter Dr Howell 
sent to you, it wou ld be a valuable asset in clearing up 
the reasons why heparin was developed by foreigners."! 
Dr McClure replied on Nov19: " I a m sorry to be so slow 
in answering your letter. I had hoped to have had tima 
to look up Dr Howell 's original letter to me, but have 
not found it, though I remember it wel l . In spite oi 
Dr Howell's advice, I did try a heparin made, supposedly] 
as you have made it. This was used on two patients with 
very severe reactions so, of course, I never repeated it, 
especially in view of Dr Howell 's opposi t ion." 
In 1980, I had some correspondence wi th Dr L.Bi 
Jaques, a biochemist who was involved in the early 
heparin work in Toronto (13). He recalled that in 1939, 
McLean came to Toronto to visit Charles Best and G o r l 
don Murray: "They 'conveniently' arranged to be out cm 
town and Arthur Charles and I were deputed to meet 
him for Sunday lunch at the Royal York." Jaques waa 
impressed in a negative way wi th McLean, who gave him 
a long tale of woe that included a divorce. 
A letter to me in June 1942 explained why he did not get 
to see the heparin exhibit in Cleveland. This letter was 
typed by him on personal stationery wi th the initials " | l 
McL." printed at the top. "Dear Doctor Lam: I thank y o i l 
for your friendly letter and for the reprints; I am sorry 
that I did not have the pleasure of meeting you at 
Atlantic City. I had intended to go to Cleveland to meet 
you and see your heparin exhibit there; but at the last 
moment, my partner who is 70 years o ld , decided to go 
and I had to stay here and attend to the pract ice—hJ 
•Ed note: Roy 0. McClure, MD, firsf Surgeon-in-Chief, Henry Ford HospltilB 
Fig 2 
McLean's autograph of the cover of a reprint of his original paper. 
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Jay McLean, Discoverer of Heparin 
decides he wil l not go to any more conventions, then at 
the last minute thinks 'Wel l ! Maybe this wi l l be my last, 
and I had better go. ' The Monday, June 8th, that the 
convention opened, he retired from practice (but not 
from the profits) so I was able only to arrive in Atlantic 
City a few hours before Macht's paper and had to leave 
that night at 6:40 pm. I d idn' t see much of the con-
vention but I met a lot of old colleagues; and that is 
really worthwhi le. . . . What luck to have Mrs Lam 
interested in your research wi th heparin. Mrs McLean, I 
fear, wishes heparin were still unknown. I sent you a 
reprint of my original article on heparin—I should have 
sent it to you and Mrs Lam (Fig 2). It was wri t ten under 
peculiar circumstances which I shall explain in a paper 
on the discovery of hepar in . " As far as I know. Jay never 
finished that paper, and we wil l probably never know 
what he meant by the last statement. 
A letter to Dr McClure dated Oct 25, 1943 had the 
letterhead "The Ohio State University, Columbus. De-
partment of Research Surgery. Chairman's Of f i ce , 
Kinsman Hal l , " but Jay had typeci the letter at home. On 
the back of the page was a long hand-written note: 
"George Curtis has appointed me associate professor 
here in his department and we have formally started on 
paper (ie, on the OSU treasurer's book) the project wi th 
a $75.00 contr ibution to erect a separate bui ld ing for 
surgical research—an Hunter ian Laboratory. If you 
should know of any way of further ing this project, wi l l 
you please wri te to George Curt is ." In his reply of Nov 
19, Dr McClure said: " I am glad you are now an Associ-
ate Professor of Surgery. I talked to Julius Stone about it 
last week, and shall further commend the surgical de-
partment to Mr Kettering* in hope that he wi l l some 
time see fit to encourage more research in that depart-
ment. . . . Can't you come up to see us?" 
Jay's responseon Nov22,1943, on plain paper: " I thank 
you deeply for your gracious letter of Nov 19. . . . The 
monograph and index and abstracts of all the heparin 
literature is a job in itself in addit ion to the research 
planned. Some of this (the laboratory experiments) I 
have interested other labs in undertaking for there are 
no facilities here for its execution. . . . Mr Stone was 
interested in heparin—in fact we thought he was going 
to finance the chemical work of which I am sending you 
a priority note we published in Science (14)—it wi l l 
appear in full in the J Am Chemical Society; but he 
couldn't and I got the Department of Chemistry, $15,000 
trom the Hoffman La Roche Company for this wo rk . " 
The company he mentioned made heparin for clinical 
use under the brand name of "L iquaemin . " Hand-
written on the margin; "Private practice has not been 
gomg so good. I am out on my own in a tough town to 
break into (since last Feb) and I get no salary as yet f rom 
the University, so I really can't afford to travel just now. 
But I'll get there if you th ink I could aid the laboratory 
project a little later. I should like to pay you a purely 
personal visit and chat about research." This sad story is 
from a 53-year-old man who should have been at the 
peak of his career (Fig 3); it adds a bitter flavor to 
Harvey's bland statement that Jay was "appointed Asso-
ciate Professor of Experimental Surgery at Ohio State 
University, remaining there for four years, 1943 to 
1947." 
By March 1944, his financial situation must have been 
better, because he did arrange the visit to Detroit. He 
called Dr McClure and asked if he could present a 
patient who had undergone treatment wi th irradiation 
at our weekly staff conference. The answer had been 
"yes" and would he also say something about heparin? 
He wrote me: "Dear Conrad Lam: I have just packed my 
bag for I am leaving tomorrow at 2 pm to attend a 
meeting of the Cleveland Radiological Society. I shall be 
at Henry Ford Hospital at 8 am Wednesday March 29 
with the patient Mr Z. I wish you would be specific on 
the 'early history' of heparin. Can you prepare ques-
tions? I do not like to waste your staff members' t ime 
with 'reminiscences.' Could you have a stenographer 
take down what I do say? Thanking for the invitation to 
speak a bit on heparin. Sincerely, Jay." 
On June 22,1945, Jay had his day (or evening) in the sun. 
Lederle Laboratories, Inc, which had a preparation of 
heparin on the market, sponsored him in their nation-
wide series of broadcasts called "The Doctors Talk It 
Over." I listened to the program and later received the 
printed transcript, which had the tit le "The Evidence for 
the Use of Heparin in Acute Coronary Thrombosis" by 
Jay McLean, M D , Associate Professor of Research Sur-
gery, Oh io State University and Discoverer of Hepar in." 
He was interviewed by the radio personality Mi l ton 
Cross. W h e n Cross asked h im to summarize. Jay 
showed surprising restraint: "The true evaluation of 
heparin in acute coronary occlusion must, of course, 
wait upon the results of clinical f indings. We know the 
nature of heparin . . . we know that it has the power to 
prevent the formation of clots . . . we know that it can 
prevent a clot, once formed, f rom growing larger . . . 
and it is reasonable to suppose that it has the effect of 
dissolving a fresh c lo t . . . we can say that here heparin 
may prove of great value." 
In 1946, Jay was coauthor of a curious paper (15) that was 
a case report of ischemic complications fol lowing a 
fracture of the lower tibia. The claim that heparin ther-
apy had reversed some of the gangrene was not sup-
ported by the evidence. 
I have no record of the exact date, but I think it was in 
1946 that McLean made his second visit to Detroit. On a 
Sunday af ternoon, I got a call f rom him from a down-
town hotel. He said he had an appointment to see 
*Ed note: Chades F. (Boss) Kettering, inventor of the self starter for the auto-
mobile and vice-president in charge of research, Ceneral Motors Corporation. 
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Dr McClure in his home, and he had neglected to bring 
a necktie. Could I help him? I took him a t ie, and I 
presume I drove him to the McClure home, although I 
do not remember the visit. I do know that the purpose 
of Jay's tr ip was to look for a job. Dr McClure was not 
interested. 
Harvey's sketch states that in 1947 McLean was "Direc-
tor of the Bureau of Cancer Control of the District of 
Columbia." In 1949 he went to Savannah where he was 
"Director of Radiation Therapy and consultant in Malig-
nant Diseases" unti l his death on Nov 14, 1957. The 
Orientacion Medica article (11) states that (translation) 
" f r o m 1949 until the moment of his death, he was 
director of the Savannah Tumor Cl in ic." Hopeful ly, the 
last seven years of his life spent in an area famous for 
southern hospitality were happier than those spent 
north of the Mason and Dixon l ine! 
Fig 3 
lay McLean in front of the Columbus (Ohio) Athletic Club, 1942 (courtesy 
of Dr Ben Wiltberger). 
In this article, I have tried to answer my question, where 
was Jay McLean in the 25 years after the "discovery" of 
heparin? The answer seems to be that he remained 
hiciden in obscurity until it became evident in 1939-1940 
that the anticoagulant prepared in Canada and Sweden 
was a valuable therapeutic agent. 
Although called "heparin," this anticoagulant is not the 
heparphosphatid or cuorin that McLean found had anti-
coagulant properties. For support for this statement, 1 
can quote two authorities. The first is Professor Howell 
himself, who on Feb 19,1924 wrote Dr Frank Hartman, 
head of the Department of Laboratories of the Henry 
Ford Hospital, "The material you obtained from 
Hynson, Wescott and Dunning is not a liver phosphatid 
prepared according to the findings of McLean. McLean 
was my pupil and was and is my friend. The work of his 
that you quote was done under my directions and ac 
cording to my methods. The small portion of it bearing 
upon liver phosphatids had nothing to do with the 
subsequent preparation of heparin. This latter sub-
stance I discovered and isolated by a method worked 
out by myself and published an account of it in the 
paper by Holt and myself" (4). McLean would not have 
agreed nor have been pleased with this, because in an 
obvious effort to reinforce the connection of his name 
with heparin, he had a rubber stamp prepared and 
stamped the following on the covers or first page of the 
reprints of his 1916 report (1), which were autographedj 
and sent to me and Dr McClure in 1941: "Cuorin 
and heparphosphatid renamed antiprothrombin(s) 
(Howell-Harvey Lecture of April 7, 1917) Anti 
prothrombin renamed heparin (Howell and Holt-Am 
Physiol. Dec 1918) see footnote p 318" (sic). 
My other authority is L.B. Jaques of the original Can^ 
adian group. In 1978 he wrote an incisive short article 
"Addendum: The Discovery of Hepar in" (16) He said 
" . . . it is still misrepresented in many current pub-
l icat ions . . . that 'hepar in was discovered by Jay 
McLean in 1916 at Johns Hopkins. ' This may be due toa 
misunderstanding of the nature of 'discovery,' or toa 
lack of the knowledge and experience with chemical 
extractions of tissues common among biochemists and 
physiologists of an earlier generat ion." After cit ing evi-
dence f rom a biochemist's vantage point, Jaques con' 
e luded , "As McLean studied a phospho l ip id anti-
coagulant, he obviously d i d not isolate heparin (italics 
his) as it has been defined since 1922. Hans Selye has 
recent ly examined the mean ing of 'd iscovery ' it* 
science. He points out that discovery is ascribed to an 
individual neither by being first in an accomplishment 
nor by correctness of ideas. Discovery in science is 
attr ibuted to the individual whose work has led directly 
to development and application, as is true of history i" 
general, eg, the discovery of America by Christopher 
Columbus in 1492. Hence, Jay McLean discovered hep-
arin (no more and no less)." 
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Ironically, the only real honor Jay ever received came six 
vears after his death. At a symposium held in his honor, 
a plaque wi th this inscr ipt ion was presented: "Jay 
McLean, 1890-1957, in recognit ion of his great con-
tribution to the discovery of heparin in collaboration 
with Professor Will iam H. Howel l , this plaque is pre-
sented to Johns Hopkins Medical School by the Confer-
ence on Bleeding in the Surgical Patient—New York 
Academy of Science—May 3,1963." I wish fate had been 
kinder to my friend Jay when he was alive. 
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